This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Super Bowl of Stents

Get ready for the next drug-coated stent showdown, which starts Sunday at the annual American College of Cardiology conference in Orlando, Fla.

The main event will be the results of a head-to-head -- or artery-to-artery -- test comparing the Cypher stent from Johnson & Johnson (JNJ - Get Report) versus the Taxus stent from Boston Scientific (BSX - Get Report).

Another big attraction features research comparing Medtronic's (MDT - Get Report) experimental Endeavor drug-coated stent with an uncoated Medtronic stent.

The stakes are big for all three companies. J&J hopes a company-financed study will help convince cardiologists to switch to Cypher from Taxus, which entered the market in March 2004, 11 months after Cypher.

Boston Scientific has shrugged off a stent recall this summer to retain its dominant position. The companies don't agree on market-share figures, but roughly speaking, Taxus has about a 2-to-1 edge.

Medtronic is hoping that its Endeavor test will provide enough compelling information to gain an accelerated review by the Food and Drug Administration. To many analysts, these results will indicate whether the company's stent enters the U.S. market in 2006 or 2007.

Every minute counts because Guidant (GDT), which is being acquired by J&J, and Abbott Laboratories (ABT) also are working on drug-coated stents.

Drug-coated stents are meshlike metal tubes inserted into arteries after vessel-clogging plaque has been removed. The stents facilitate blood flow and reduce the risk of heart attack. The drug-coated stents, also known as drug-eluting stents, release chemicals into the arteries periodically to reduce the risk of arteries reclogging. Uncoated stents reduce the reclogging risk, too, but the drug-coated devices do a better job.

The Cypher versus Taxus performance will be unveiled via a J&J-sponsored test nicknamed Reality. "Even if the data revealed slightly more favorable, non-significant trends for Cypher, the difference ... is likely not enough to induce a material shift away from Taxus use," said a recent research report from Goldman Sachs. And if Cypher's results appeared slightly better, "Taxus use is likely to be dictated more so by the delivery/flexibility" of the Taxus delivery system.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BSX $18.32 0.00%
JNJ $102.04 0.00%
MDT $76.56 0.00%
AAPL $118.88 0.00%
FB $105.74 0.00%


Chart of I:DJI
DOW 17,812.19 +19.51 0.11%
S&P 500 2,089.14 +2.55 0.12%
NASDAQ 5,102.8080 +0.33 0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs